WallStSmart

CVRx Inc (CVRX)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 35414% more annual revenue ($20.98B vs $59.07M). GEHC leads profitability with a 9.1% profit margin vs -89.1%. GEHC earns a higher WallStSmart Score of 57/100 (C).

CVRX

Avoid

29

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.7Quality: 4.5
Piotroski: 3/9Altman Z: -7.47

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CVRXUndervalued (+71.4%)

Margin of Safety

+71.4%

Fair Value

$21.26

Current Price

$5.38

$15.88 discount

UndervaluedFair: $21.26Overvalued

Intrinsic value data unavailable for GEHC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CVRX1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
19.6%8/10

19.6% revenue growth

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Areas to Watch

CVRX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$156.03M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-180.9%2/10

ROE of -180.9% — below average capital efficiency

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.844/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CVRX

The strongest argument for CVRX centers on Revenue Growth. Revenue growth of 19.6% demonstrates continued momentum.

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bear Case : CVRX

The primary concerns for CVRX are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.03 is elevated, increasing financial risk.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

CVRX profiles as a growth stock while GEHC is a value play — different risk/reward profiles.

GEHC carries more volatility with a beta of 0.86 — expect wider price swings.

CVRX is growing revenue faster at 19.6% — sustainability is the question.

GEHC generates stronger free cash flow (112M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (57/100 vs 29/100). CVRX offers better value entry with a 71.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CVRx Inc

HEALTHCARE · MEDICAL DEVICES · USA

CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?